IDEXX Laboratories Inc

More Details of IDEXX Laboratories Inc Company

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

Company Info

Ticker SymbolIDXX

Company nameIDEXX Laboratories Inc

IPO dateJun 21, 1991

Founded at1983

CEOMr. Andrew Emerson

Number of employees11000

Security typeOrdinary Share

Fiscal year-endJun 21

AddressOne Idexx Drive

CityWESTBROOK

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code04092-2041

Phone12075560300

Websitehttps://www.idexx.com/

Ticker SymbolIDXX

IPO dateJun 21, 1991

Founded at1983

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

+0.61%

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

5.93K

+8.90%

Mr. Daniel M. (Dan) Junius

Independent Director

3.00K

+9.56%

Mr. Andrew Emerson

Executive Vice President, Chief Executive Officer, Treasurer

2.40K

--

Mr. Michael Schreck

Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience

1.92K

+112.86%

Mr. Bruce L. Claflin

Independent Director

1.72K

--

Dr. Stuart M. Essig, Ph.D.

Independent Director

1.09K

+31.76%

Name

Name/Position

Position

Shareholding

Change

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

+0.61%

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

5.93K

+8.90%

Mr. Daniel M. (Dan) Junius

Independent Director

3.00K

+9.56%

Revenue Breakdown

Currency: USDUpdated: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

CAG Diagnostics recurring revenue

3.13B

80.29%

Reference laboratory diagnostic and consulting services

1.34B

34.28%

IDEXX VetLab consumables

1.30B

33.44%

Rapid assay products

359.75M

9.23%

CAG Diagnostics capital - instruments

312.62M

8.02%

Other

-2.54B

-65.27%

By RegionUSD

Name

Revenue

Proportion

United States

2.53B

64.99%

Other Euorpe

196.31M

5.04%

Germany

173.68M

4.46%

Canada

152.88M

3.92%

United Kingdom

134.63M

3.45%

Other

706.82M

18.14%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

CAG Diagnostics recurring revenue

3.13B

80.29%

Reference laboratory diagnostic and consulting services

1.34B

34.28%

IDEXX VetLab consumables

1.30B

33.44%

Rapid assay products

359.75M

9.23%

CAG Diagnostics capital - instruments

312.62M

8.02%

Other

-2.54B

-65.27%

Shareholding Stats

Updated: Sat, May 17

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

12.21%

BlackRock Institutional Trust Company, N.A.

6.76%

State Street Global Advisors (US)

4.54%

Fundsmith LLP

3.29%

Geode Capital Management, L.L.C.

3.00%

Other

70.20%

Shareholders

Proportion

The Vanguard Group, Inc.

12.21%

BlackRock Institutional Trust Company, N.A.

6.76%

State Street Global Advisors (US)

4.54%

Fundsmith LLP

3.29%

Geode Capital Management, L.L.C.

3.00%

Other

70.20%

Shareholder Types

Shareholders

Proportion

Investment Advisor

44.48%

Investment Advisor/Hedge Fund

41.16%

Research Firm

4.01%

Pension Fund

2.24%

Bank and Trust

2.04%

Hedge Fund

1.86%

Sovereign Wealth Fund

1.35%

Individual Investor

0.68%

Family Office

0.48%

Other

1.71%

Institutional Shareholding

Updated: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2230

77.53M

95.67%

-2.91M

2024Q4

2242

76.14M

93.59%

-5.30M

2024Q3

2152

77.90M

94.66%

-4.67M

2024Q2

2140

80.09M

96.98%

-924.14K

2024Q1

2154

77.56M

93.40%

-2.57M

2023Q4

2187

77.94M

93.84%

-2.83M

2023Q3

2153

79.23M

95.34%

-677.16K

2023Q2

2157

77.53M

93.40%

-1.56M

2023Q1

2158

77.14M

92.96%

-2.07M

2022Q4

2124

77.44M

93.49%

-2.66M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

9.67M

11.94%

-29.32K

-0.30%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.32M

6.57%

-239.97K

-4.31%

Dec 31, 2024

State Street Global Advisors (US)

3.64M

4.49%

+24.20K

+0.67%

Dec 31, 2024

Fundsmith LLP

2.66M

3.29%

-1.31K

-0.05%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.30M

2.83%

+37.73K

+1.67%

Dec 31, 2024

Baron Capital Management, Inc.

2.01M

2.47%

+82.26K

+4.28%

Dec 31, 2024

T. Rowe Price Associates, Inc.

1.05M

1.29%

-375.34K

-26.42%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

1.69M

2.09%

+22.74K

+1.36%

Feb 28, 2025

BlackRock Asset Management Ireland Limited

1.13M

1.39%

+36.40K

+3.33%

Dec 31, 2024

Principal Global Investors (Equity)

711.20K

0.88%

-19.27K

-2.64%

Dec 31, 2024

Related ETFs

Updated: Fri, Jun 6

Name

Proportion

ProShares Pet Care ETF

11.01%

iShares U.S. Medical Devices ETF

5.07%

First Trust Water ETF

4.92%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

2.24%

SPDR S&P Health Care Equipment ETF

2.22%

Putnam Sustainable Future ETF

2.11%

Invesco S&P 500 Equal Weight Health Care ETF

2.1%

First Trust S&P 500 Economic Moat Index ETF

2.04%

American Century Mid Cap Growth Impact ETF

1.93%

Adaptive Core ETF

1.84%

ProShares Pet Care ETF

Proportion11.01%

iShares U.S. Medical Devices ETF

Proportion5.07%

First Trust Water ETF

Proportion4.92%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

Proportion2.24%

SPDR S&P Health Care Equipment ETF

Proportion2.22%

Putnam Sustainable Future ETF

Proportion2.11%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion2.1%

First Trust S&P 500 Economic Moat Index ETF

Proportion2.04%

American Century Mid Cap Growth Impact ETF

Proportion1.93%

Adaptive Core ETF

Proportion1.84%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

527.187USD

IDEXX Laboratories Inc

527.187

Overview

Company